RCS - Abingdon Health PLC - Launch of Abingdon Simply Test e-commerce website

Abingdon HealthAnnouncement

21/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220721:nRSU2113Ta&default-theme=true

RNS Number : 2113T  Abingdon Health PLC  21 July 2022

Abingdon Health plc

("Abingdon" or "the Company")

 

Launch of Abingdon Simply Test e-commerce website

 

York, U.K. 21 July 2022: Abingdon Health plc (AIM: ABDX), a leading
international developer and manufacturer of high quality and effective rapid
tests, announces the launch of its new B2C e-commerce website,
abingdonsimplytest.com (https://www.abingdonsimplytest.com) .

 

The Abingdon Simply Test website will provide UK and international customers
with Abingdon Simply Test and Abingdon-assured third-party branded self-tests.
All products will be regulatory approved and manufactured under international
quality management systems.

 

The e-commerce site has launched with a range of tests in areas such as
fertility, health and well-being and infectious disease. It is Abingdon's
intention to broaden the range of available tests, with a focus on
self-testing.

 

The Abingdon Simply Test website will provide consumers with simple,
jargon-free information to enable them to make considered purchasing
decisions. All tests on the abingdonsimplytest.com
(http://www.abingdonsimplytest.com) site will also have undergone Abingdon's
10-point evaluation covering quality, regulatory and usability requirements to
provide customers with greater assurance on the quality of these tests.

 

Self-testing is a major growth area within the global diagnostic market and in
its recent report, Future Market Insights forecast the global market for
self-testing kits will be worth US $11bn by 2030(1). Lateral flow testing has
seen a significant increase in profile and familiarity following the rapid
expansion of COVID-19 lateral flow self-testing during the pandemic. The
increased awareness amongst the general public of lateral flow testing coupled
with its benefits such as low cost and ease-of-use means that LFT testing will
play a major role in the democratisation of testing and the empowerment of
individuals to manage their own health.

 

Chris Yates, CEO of Abingdon Health plc, commented: "The healthcare landscape
is changing and the increase in lateral flow testing during the COVID-19
pandemic has served as a catalyst for a paradigm shift in moving diagnostic
testing out of the laboratory and into the home. Consumers are increasingly
taking a more, proactive approach to managing their health and wellbeing and
this is leading to the growth of the self-health and self-testing market. The
launch of our Abingdon Simply Test site will provide focal point for consumers
wishing to purchase lateral flow self-tests and will support people in taking
an empowered role in managing their own health and wellbeing."

 

(1) https://www.futuremarketinsights.com/reports/self-testing-market
(https://www.futuremarketinsights.com/reports/self-testing-market)

 

Enquiries:

 

 Abingdon Health plc                                                                 www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Yates, Chief Executive Officer                                                Via Walbrook PR
 Melanie Ross, Chief Financial Officer
 Dr Chris Hand, Non-Executive Chairman

 Singer Capital Markets (Sole Broker and Nominated Adviser)                          Tel: +44 (0)20 7496 3000
 Peter Steel, Alex Bond, Sam Butcher (Corporate Finance)
 Tom Salvesen (Corporate Broking)

 Walbrook PR Limited                                    Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                                        (mailto:abingdon@walbrookpr.com)
 Paul McManus / Phillip Marriage  Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082
 Alice Woodings                   Mob: +44 (0)7407 804 654

 
About Abingdon Health

 

Abingdon Health is a world leading developer and manufacturer of high-quality
lateral flow rapid tests (https://www.abingdonhealth.com/services/) across all
industry sectors, including healthcare and COVID-19. Abingdon is the partner
of choice for a growing global customer base and takes projects from initial
concept through to routine and large-scale manufacturing and has also
developed and marketed its own labelled tests.

The Company offers product development, regulatory support, technology
transfer and manufacturing services for customers looking to develop new
assays or transfer existing laboratory-based assays to a lateral flow format.
Abingdon Health aims to support the increase in need for rapid results across
many industries and locations and produces lateral flow tests in areas such as
infectious disease, clinical testing including companion diagnostics, animal
health and environmental testing. Faster access to results allows for rapid
decision making, targeted intervention and can support better outcomes. This
ability has a significant role to play in improving life across the world. To
support this aim Abingdon Health has also developed AppDx(®), a customisable
image capturing technology that transforms a smartphone into a
self-sufficient, standalone lateral-flow reader.

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit: www.abingdonhealth.com
(http://www.abingdonhealth.com/)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPPUPCMUPPGMU